|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schultheiß M, Bengsch B and Thimme R:
Hepatocellular carcinoma. Dtsch Med Wochenschr. 146:1411–1420.
2021.(In German). PubMed/NCBI
|
|
3
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J; EASL Panel of Experts on HCC, : Clinical management of
hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL
conference. European association for the study of the liver. J
Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Bru C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang XX, Ni B, Li Q, Hu LP, Jiang SH, Li
RK, Tian GA, Zhu LL, Li J, Zhang XL, et al: GPAA1 promotes gastric
cancer progression via upregulation of GPI-anchored protein and
enhancement of ERBB signalling pathway. J Exp Clin Cancer Res.
38:2142019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang JX, Wang JH, Sun XG and Hou TZ:
GPAA1 promotes progression of childhood acute lymphoblastic
leukemia through regulating c-myc. Eur Rev Med Pharmacol Sci.
24:4931–4939. 2020.PubMed/NCBI
|
|
7
|
Wu G, Guo Z, Chatterjee A, Huang X, Rubin
E, Wu F, Mambo E, Chang X, Osada M, Sook Kim M, et al:
Overexpression of glycosylphosphatidylinositol (GPI) transamidase
subunits phosphatidylinositol glycan class T and/or GPI anchor
attachment 1 induces tumorigenesis and contributes to invasion in
human breast cancer. Cancer Res. 66:9829–9836. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ho JC, Cheung ST, Patil M, Chen X and Fan
ST: Increased expression of glycosyl-phosphatidylinositol anchor
attachment protein 1 (GPAA1) is associated with gene amplification
in hepatocellular carcinoma. Int J Cancer. 119:1330–1337. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baralle FE and Giudice J: Alternative
splicing as a regulator of development and tissue identity. Nat Rev
Mol Cell Biol. 18:437–451. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang GS and Cooper TA: Splicing in
disease: Disruption of the splicing code and the decoding
machinery. Nat Rev Genet. 8:749–761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grosso AR, Martins S and Carmo-Fonseca M:
The emerging role of splicing factors in cancer. EMBO Rep.
9:1087–1093. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim E, Goren A and Ast G: Insights into
the connection between cancer and alternative splicing. Trends
Genet. 24:7–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen Q and Nam SW: SF3B4 as an early-stage
diagnostic marker and driver of hepatocellular carcinoma. BMB Rep.
51:57–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iguchi T, Komatsu H, Masuda T, Nambara S,
Kidogami S, Ogawa Y, Hu Q, Saito T, Hirata H, Sakimura S, et al:
Increased copy number of the gene encoding SF3B4 indicates poor
prognosis in hepatocellular carcinoma. Anticancer Res.
36:2139–2144. 2016.PubMed/NCBI
|
|
15
|
Shen Q, Eun JW, Lee K, Kim HS, Yang HD,
Kim SY, Lee EK, Kim T, Kang K, Kim S, et al: Barrier to
autointegration factor 1, procollagen-lysine, 2-oxoglutarate
5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage
cancer decision markers and drivers of hepatocellular carcinoma.
Hepatology. 67:1360–1377. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kidogami S, Iguchi T, Sato K, Yoshikawa Y,
Hu Q, Nambara S, Komatsu H, Ueda M, Kuroda Y, Masuda T, et al:
SF3B4 plays an oncogenic role in esophageal squamous cell
carcinoma. Anticancer Res. 40:2941–2946. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou W, Ma N, Jiang H, Rong Y, Deng Y,
Feng Y, Zhu H, Kuang T, Lou W, Xie D and Wang D: SF3B4 is decreased
in pancreatic cancer and inhibits the growth and migration of
cancer cells. Tumour Biol. 39:10104283176959132017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vainauskas S, Maeda Y, Kurniawan H,
Kinoshita T and Menon AK: Structural requirements for the
recruitment of Gaa1 into a functional glycosylphosphatidylinositol
transamidase complex. J Biol Chem. 277:30535–30542. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Capurro M, Wanless IR, Sherman M, Deboer
G, Shi W, Miyoshi E and Filmus J: Glypican-3: A novel serum and
histochemical marker for hepatocellular carcinoma.
Gastroenterology. 125:89–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen G, Li SY, Cai HY and Zuo FY: Enhanced
expression and significance of glycosylphosphatidylinositol anchor
attachment protein 1 in colorectal cancer. Genet Mol Res.
13:499–507. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing S, Li Z, Ma W, He X, Shen S, Wei H,
Li ST, Shu Y, Sun L, Zhong X, et al: DIS3L2 promotes progression of
hepatocellular carcinoma via hnRNP U-Mediated alternative splicing.
Cancer Res. 79:4923–4936. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oltean S and Bates DO: Hallmarks of
alternative splicing in cancer. Oncogene. 33:5311–5318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee SE, Alcedo KP, Kim HJ and Snider NT:
Alternative splicing in hepatocellular carcinoma. Cell Mol
Gastroenterol Hepatol. 10:699–712. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu W, Huang H, Yu L and Cao L:
Meta-analysis of gene expression profiles indicates genes in
spliceosome pathway are up-regulated in hepatocellular carcinoma
(HCC). Med Oncol. 32:962015. View Article : Google Scholar : PubMed/NCBI
|
